Cinqair (Reslizumab) is considered relevant in conditions characterized by periods of heightened symptoms, specifically as an add-on maintenance therapy for severe asthma in adults (aged 18 years and older) when the condition is associated with high levels of eosinophils. It is commonly used when short-term symptomatic assistance is needed to help manage this severe, chronic condition.

---

Therapeutic Role and Key Benefits

Cinqair is generally applied across domains where additional symptomatic support is needed in cases of severe asthma. It is generally applied when the condition involves inflammatory processes linked to specific biological markers. The therapeutic focus is on easing the overall symptom load by helping to reduce the rate of clinically severe asthma exacerbations and supporting maintenance of functional stability.

The brief listing of indications includes severe eosinophilic asthma and uncontrolled disease activity in situations where patients experience recurring severe symptoms. This supportive role helps patients cope more steadily with symptom fluctuations in their day-to-day lives.

“This approach is relevant for managing symptoms that interfere with daily comfort, providing support when chronic breathing symptoms become difficult to manage.”

Quick Fact: Relief for Asthma Exacerbations
Main Benefit	Provides support that helps ease the overall symptom burden by reducing the frequency of severe asthma attacks.
Use Context	Applied during phases when symptoms become more noticeable and when long-term management of discomfort is required.
Target Symptom	Recurrent, clinically severe asthma exacerbations.

Cinqair (reslizumab) is a medication with specific regulatory requirements defining the patient population eligible for treatment.

Populations Excluded from Use

Contraindications: Cinqair is strictly contraindicated for patients with a known hypersensitivity or allergy to reslizumab or any of its excipients.

Limitations of Use: The medicine must not be used for the relief of acute bronchospasm or status asthmaticus, or to treat other eosinophilic conditions. It is only approved as an add-on maintenance treatment for severe asthma.

Required Eligibility and Conditional Use

Age Requirement: The safety and effectiveness of Cinqair have been established only in patients aged 18 years and older; its use in pediatric patients is not established.

Infection Status: Patients with a pre-existing parasitic (helminth) infection must be treated for the infection prior to starting Cinqair. If an infection occurs during therapy and does not respond to treatment, the use of Cinqair should be discontinued until the infection resolves.

Pregnancy and Lactation: Use during pregnancy is generally not recommended unless the potential benefit justifies the potential risk. It is unknown if the medicine is excreted into breast milk, and caution is advised during lactation.

Cinqair (reslizumab) is a targeted biologic medicine, and its interaction profile differs from many conventional drugs. Official regulatory information indicates that no formal clinical drug interaction studies have been conducted. The documented profile focuses on administration rules and required management of concurrent conditions.

Pharmacokinetic Profile

Population pharmacokinetic analyses confirm that the co-administration of common asthma therapies does not affect the exposure of reslizumab. Specifically, official data show that concurrent use of systemic corticosteroids and leukotriene antagonists does not alter the drug's pharmacokinetics. Furthermore, based on laboratory testing, the drug is considered unlikely to affect the activity of key metabolic enzymes, including CYP1A2, CYP3A4, and CYP2B6.

Administration and Treatment Restrictions

A mandatory Administration Compatibility rule states that Cinqair must not be infused simultaneously in the same intravenous line with any other medicinal products or agents.

An important Required Pre-treatment Restriction exists regarding parasitic infections. Patients with a known pre-existing helminth infection must be treated before starting Cinqair. If a patient develops a persistent helminth infection during treatment, temporary discontinuation of Cinqair is required until the infection is resolved.

The safety and efficacy profile is unknown when Cinqair is used with other immunosuppressant medicinal products or live vaccines, as these specific combinations have not been studied. The medicine is contraindicated only for those with a known hypersensitivity to the drug or its excipients.

Targeted IL-5 Neutralization

Cinqair (Reslizumab) acts as a highly selective, functional antagonist by binding directly to and neutralizing the circulating Interleukin-5 (IL-5) cytokine. This molecular interaction prevents IL-5 from activating the IL-5 receptor alpha chain (IL-5Rα) on eosinophil precursor cells, which halts the signaling that normally drives cellular development.

---

Interruption of the Eosinophil Life Cycle Cascade

The inhibition of IL-5 signaling interrupts the eosinophil life cycle cascade. Since IL-5 is the major cytokine responsible for the maturation, proliferation, and survival of eosinophils, blocking it accelerates their natural programmed cell death (apoptosis) and restricts their production in the bone marrow.

---

Systemic Eosinophil Depletion

This mechanism leads to a rapid, systemic depletion of circulating eosinophil counts and a reduction of these cells in affected tissues. This change in cellular population modulates the underlying eosinophil-driven inflammatory process. The mechanism is physiologically constrained to processes dependent on the IL-5/Eosinophil axis and is not applicable for rapid physiological events mediated by non-immunological pathways, such as smooth muscle contraction.

How Cinqair (Reslizumab) is Used

Cinqair is used strictly according to a highly standardized protocol defined by its pharmaceutical form as a concentrate for solution for intravenous infusion. As an add-on maintenance treatment, its administration is managed by a healthcare professional in a clinical setting; it is not intended for self-administration.

---

Administration and Dosing Schedule

The officially approved route of administration for Cinqair is strictly intravenous (IV) infusion. The medication follows a fixed weight-based regimen, administered on a continuous, cyclic schedule.

Usage Parameter	Instruction
Dose	3.0 mg per kilogram of body weight (3.0 mg/kg)
Frequency	Administered once every four weeks (monthly)
Route	Intravenous Infusion only

---

Preparation and Procedural Constraints

Cinqair is supplied in single-use vials and requires mandatory preparation before use. The concentrate must be diluted with 0.9% Sodium Chloride solution prior to infusion. Administration must be performed over a controlled period, typically lasting 5 to 50 minutes, and is not permitted as an IV push or bolus. To maintain the integrity and purity of the biologic, the infusion must be delivered through an intravenous line fitted with a sterile, low-protein binding in-line filter. The product should also not be mixed with other medicinal products.

---

Population and Missed Doses

No dose adjustment is required for older adults (age 65 years and older) or for patients with renal or hepatic impairment. If a scheduled dose is missed, it should be administered as soon as possible, with the four-week dosing interval then being restarted from that new date of administration.

Research Evidence / Overview of Studies for Cinqair

Evidence for Use in Severe Eosinophilic Asthma

The clinical evaluation of Cinqair (reslizumab) primarily involves randomized, double-blind, placebo-controlled Phase 3 trials. This rigorous type of research was applied in studies examining severe asthma in adults (18 years and older) whose symptoms were not adequately controlled by standard inhaled corticosteroid therapy plus another controller medication. A key requirement for patients to participate was evidence of the eosinophilic phenotype, meaning they had high levels of eosinophils in their blood.

These studies monitored the patients over defined time intervals, with the main pivotal trials spanning 52 weeks (one year). Researchers primarily focused on the frequency of clinically significant asthma exacerbations and changes in lung function ( FEV1). Studies examined how frequently asthma exacerbations occurred, and the findings described patterns where the group receiving reslizumab showed fewer reported exacerbations over the study period compared to the placebo group. Studies monitored changes in lung function throughout the study period.

---

Study Outcomes Beyond Exacerbations

In addition to examining the frequency of acute episodes, studies explored how Cinqair was associated with other important aspects of living with severe asthma. Research focused on changes measured using standardized patient-reported experiences, specifically the Asthma Control Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ). Studies reported how symptoms evolved, and the evidence contributes to understanding patient-reported symptom patterns.

Furthermore, a dedicated research focus involved patients whose asthma required the use of maintenance oral corticosteroids (OCS). Findings described patterns where the research assessed the change in daily OCS dose in the reslizumab groups versus the placebo groups, noting the proportion of patients in whom a reduction in the OCS dose was observed.

---

Research Gaps and What Remains Uncertain

The overall evidence base is highly specific, and the results apply only to the populations studied: those with severe, uncontrolled asthma clearly defined by the eosinophilic phenotype. Long-term effects on physical discomfort or how symptoms change over many years are not fully established based on the most rigorous, placebo-controlled trial data, though longer open-label studies exist.

Data for Cinqair are insufficient for use in pediatric patients (under 18 years old). Moreover, there are limited direct, head-to-head research comparisons between Cinqair and other biologic medicines used for severe asthma.

Key Studies & References

1. Effect of reslizumab on oral corticosteroid-dependent patients with severe eosinophilic asthma: a randomized, placebo-controlled clinical trial
2. NICE technology appraisal guidance [TA431]: Reslizumab for treating severe eosinophilic asthma

Common questions about Cinqair (FAQ)

---

Q: What is an 'add-on maintenance treatment' for asthma?

A: Cinqair is officially designated as an add-on maintenance therapy. This means the medicine is described as being used in conjunction with a patient’s standard asthma control medications, rather than as a replacement for them. The treatment is intended to help maintain control over a severe, chronic condition.

Q: What is the expected timeline to start noticing effects from Cinqair?

A: Studies and official information indicate that an effect on lung function and the frequency of asthma flare-ups was observed starting at the first observation period of four weeks. This pattern of effect was observed to be sustained throughout the duration of the pivotal clinical studies.

Q: Are there any long-term safety concerns associated with using Cinqair?

A: Official research results are primarily based on rigorous, placebo-controlled studies lasting up to one year. Data on the long-term effects of using the medication over many years are not fully established by the most rigorous trials, though some longer-term open-label studies have also been performed.

Q: Is it necessary to have certain lab tests done before starting Cinqair?

A: Official guidance requires evidence of the eosinophilic phenotype before beginning treatment. This evidence is generally established by a blood test showing a high level of eosinophils in the blood. Official information states that any pre-existing parasitic (helminth) infection is required to be treated before Cinqair administration.

Q: Why do official sources sometimes mention 'eosinophilic phenotype' for Cinqair?

A: Cinqair is a targeted biologic medicine designed to work by neutralizing Interleukin-5 (IL-5), a protein that drives the growth of inflammatory cells called eosinophils. Therefore, the medicine is indicated only for conditions where evidence confirms that high eosinophil levels are a major contributor to the disease.

Q: What information is available about Cinqair's effects on liver function?

A: Official information indicates that no dose adjustment is needed for patients with hepatic (liver) impairment. Furthermore, laboratory testing suggests the drug is considered unlikely to affect the activity of the key liver enzymes that metabolize many common medicines.

Q: Why is it important to continue using quick-relief inhalers while on Cinqair?

A: Cinqair is approved only as a maintenance treatment and is not intended for the rapid relief of sudden or acute asthma symptoms, such as a severe flare-up. Official documents describe Cinqair as not being for acute symptoms, emphasizing that quick-relief inhalers should continue to be available for sudden breathing problems.

Q: How is Cinqair different from other add-on asthma treatments?

A: Cinqair is a targeted biologic medicine classified as an Interleukin-5 (IL-5) antagonist. This type of medicine is generally distinguished from conventional treatments—like inhaled corticosteroids or leukotriene modifiers—by its specific molecular mechanism of targeting and neutralizing a specific inflammatory protein (IL-5).

Q: Is Cinqair the same kind of medicine as Xolair or Nucala?

A: Cinqair (Reslizumab) is in the class of targeted monoclonal antibodies, which includes other similar biologics. Cinqair is specifically characterized as an Interleukin-5 (IL-5) antagonist, meaning its action is to block the IL-5 cytokine, which is one specific type of inflammatory protein.

Q: Can Cinqair affect the immune system?

A: Cinqair is designed to modulate a specific part of the inflammatory response by reducing the number of eosinophils, which are a type of immune cell. Its effect is constrained to the processes dependent on the Interleukin-5 (IL-5) pathway, which is involved in eosinophil activity.

Q: Are there any specific supplements or vitamins that should be avoided while using Cinqair?

A: The official prescribing information does not list specific supplements or vitamins to avoid. However, regulatory patient counseling information includes a general recommendation to inform a healthcare provider about all medicines, over-the-counter drugs, vitamins, and herbal products being used.

Q: What is known about Cinqair interacting with common pain relievers like Tylenol (acetaminophen)?

A: Official documents state that no formal clinical drug interaction studies have been conducted with this medicine. However, based on laboratory testing, the drug is considered unlikely to affect the activity of the key metabolic enzymes involved in the processing of many common medicines, including pain relievers.

Q: Does Cinqair interact with common blood pressure medications?

A: Official documents state that no formal clinical drug interaction studies have been conducted. In general, concurrent use of common asthma therapies does not affect the drug's exposure, and Cinqair is considered unlikely to affect the activity of the key metabolic enzymes that process many common drugs like blood pressure medications.

Q: Is Cinqair treatment permanent, or can I stop using it later?

A: Cinqair is designed as an add-on maintenance treatment. Official documents indicate that treatment should be discontinued immediately if a patient exhibits signs of anaphylaxis or if a persistent helminth infection (parasite) does not resolve with treatment.

Q: What does 'refractory' asthma mean in the context of Cinqair?

A: While the specific clinical term 'refractory' is not used in the prescribing information, the medicine is indicated for use in patients whose severe asthma is not adequately controlled by their current standard medications. This describes the population for whom the medicine is officially approved.

Q: Can I use Cinqair if I have another chronic lung condition like COPD?

A: Cinqair is only indicated for the add-on maintenance treatment of severe asthma with an eosinophilic phenotype. It is not indicated for the treatment of other eosinophilic conditions or other chronic lung conditions.

Q: What happens if I stop taking my other asthma medicines after starting Cinqair?

A: Cinqair is designated as an add-on maintenance treatment. Official documentation specifies that other asthma medications, particularly corticosteroids (inhaled or oral), must not be discontinued or reduced without the specific guidance of a healthcare professional.

Q: What is the risk of having an asthma attack while receiving a Cinqair infusion?

A: The most significant safety concern during or shortly after the infusion is the risk of anaphylaxis and acute hypersensitivity reactions. The infusion must be conducted in a healthcare setting prepared to manage these acute reactions.

Q: Is it necessary to wait at the clinic after the Cinqair infusion is complete?

A: Official warnings mandate that the patient remain under observation for an appropriate period of time following Cinqair administration. This is a required precaution due to the documented risk of anaphylaxis, which may occur during or shortly after the intravenous infusion.

Q: What are common patient misunderstandings about Cinqair's purpose?

A: The medicine is sometimes misunderstood as a quick-relief medicine or a general steroid treatment. Cinqair is officially designated as a targeted add-on maintenance treatment and must not be used for the relief of acute asthma symptoms.

Q: Can a patient travel easily while on a Cinqair treatment schedule?

A: The required administration of the medicine is via intravenous infusion by a healthcare professional in a clinical setting once every four weeks. Planning for travel should consider this strict required schedule and the specialized administration setting.

Q: Does Cinqair affect the ability to drive or operate machinery?

A: Based on the safety profile documented in clinical trials, it is considered unlikely that Cinqair will affect a person's ability to drive or safely operate machinery.

Cinqair concentrate vials must be strictly stored in the refrigerator between 2 C and 8 C (36 F to 46 F). Freezing the product is prohibited by regulatory labeling. Vials must be stored in the original carton to protect the contents from light.

Stability and Handling

The product is supplied in a single-use vial. Once the concentrate is diluted for intravenous infusion, the total time for storage and administration must not exceed 16 hours. The diluted solution can be stored during this period either refrigerated (2 C to 8 C) or at room temperature (up to 25 C), and it must also be protected from light.

Disposal

Any unused portion of the product remaining in the single-use vial after the required dose is withdrawn must be discarded. Disposal of the unused medicinal product and any waste materials must be carried out in accordance with local requirements for pharmaceutical waste.